Santen Pharmaceutical Co. Ltd
Santen Pharmaceutical Co., Ltd. engages in the research and development, manufacturing, and marketing of pharmaceuticals and medical devices in Japan, China, Asia, Europe, the Middle East, Africa, and internationally. Its product portfolio includes tafluprost/timolol maleate, a prostaglandin F2a derivative and a beta-adrenergic receptor blocker for the treatment of glaucoma and ocular hypertensio… Read more
Market Cap & Net Worth: Santen Pharmaceutical Co. Ltd (SNPHF)
Santen Pharmaceutical Co. Ltd (PINK:SNPHF) has a market capitalization of $3.55 Billion ($3.55 Billion) as of March 18, 2026. Listed on the PINK stock exchange, this USA-based company holds position #3593 globally and #2343 in its home market, demonstrating a 0.00% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Santen Pharmaceutical Co. Ltd's stock price $10.53 by its total outstanding shares 336988992 (336.99 Million).
Santen Pharmaceutical Co. Ltd Market Cap History: 2015 to 2025
Santen Pharmaceutical Co. Ltd's market capitalization history from 2015 to 2025. Data shows change from $4.57 Billion to $3.55 Billion (-0.46% CAGR).
Santen Pharmaceutical Co. Ltd Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Santen Pharmaceutical Co. Ltd's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
0.01x
Santen Pharmaceutical Co. Ltd's market cap is 0.01 times its annual revenue
0.84x
Lower than industry averageLatest Price to Earnings (P/E) Ratio
0.10x
Santen Pharmaceutical Co. Ltd's market cap is 0.10 times its annual earnings
11.15x
Lower than industry averageWhat These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2016 | $3.41 Billion | $195.29 Billion | $53.37 Billion | 0.02x | 0.06x |
| 2017 | $4.43 Billion | $199.10 Billion | $21.72 Billion | 0.02x | 0.20x |
| 2018 | $4.47 Billion | $224.94 Billion | $35.26 Billion | 0.02x | 0.13x |
| 2019 | $5.13 Billion | $234.03 Billion | $31.95 Billion | 0.02x | 0.16x |
| 2020 | $4.99 Billion | $241.56 Billion | $23.62 Billion | 0.02x | 0.21x |
| 2021 | $3.80 Billion | $249.60 Billion | $6.83 Billion | 0.02x | 0.56x |
| 2022 | $2.62 Billion | $266.26 Billion | $27.22 Billion | 0.01x | 0.10x |
| 2023 | $3.29 Billion | $279.04 Billion | -$14.95 Billion | 0.01x | N/A |
| 2024 | $3.42 Billion | $301.96 Billion | $26.64 Billion | 0.01x | 0.13x |
| 2025 | $3.55 Billion | $300.00 Billion | $36.26 Billion | 0.01x | 0.10x |
Competitor Companies of SNPHF by Market Capitalization
Companies near Santen Pharmaceutical Co. Ltd in the global market cap rankings as of March 18, 2026.
Key companies related to Santen Pharmaceutical Co. Ltd by market ranking:
- Eli Lilly and Company (NYSE:LLY): Ranked #15 globally with a market cap of $883.37 Billion USD.
- Johnson & Johnson (NYSE:JNJ): Ranked #18 globally with a market cap of $574.95 Billion USD.
- AbbVie Inc (NYSE:ABBV): Ranked #29 globally with a market cap of $390.88 Billion USD.
- AstraZeneca PLC (NASDAQ:AZN): Ranked #46 globally with a market cap of $296.35 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #15 | Eli Lilly and Company | NYSE:LLY | $883.37 Billion | $989.12 |
| #18 | Johnson & Johnson | NYSE:JNJ | $574.95 Billion | $243.19 |
| #29 | AbbVie Inc | NYSE:ABBV | $390.88 Billion | $221.45 |
| #46 | AstraZeneca PLC | NASDAQ:AZN | $296.35 Billion | $192.01 |
Santen Pharmaceutical Co. Ltd Historical Marketcap From 2015 to 2025
Between 2015 and today, Santen Pharmaceutical Co. Ltd's market cap moved from $4.57 Billion to $ 3.55 Billion, with a yearly change of -0.46%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2025 | $3.55 Billion | +3.74% |
| 2024 | $3.42 Billion | +4.10% |
| 2023 | $3.29 Billion | +25.40% |
| 2022 | $2.62 Billion | -30.99% |
| 2021 | $3.80 Billion | -23.94% |
| 2020 | $4.99 Billion | -2.67% |
| 2019 | $5.13 Billion | +14.69% |
| 2018 | $4.47 Billion | +0.87% |
| 2017 | $4.43 Billion | +30.19% |
| 2016 | $3.41 Billion | -25.52% |
| 2015 | $4.57 Billion | -- |
End of Day Market Cap According to Different Sources
On Mar 17th, 2026 the market cap of Santen Pharmaceutical Co. Ltd was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $3.55 Billion USD |
| MoneyControl | $3.55 Billion USD |
| MarketWatch | $3.55 Billion USD |
| marketcap.company | $3.55 Billion USD |
| Reuters | $3.55 Billion USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.